First-time disclosure of Clinical Candidate live tweeting-UPDATED

UPDATED: Sep. 7- You can now find structures for the drug candidates disclosed at the symposium in this pdf document. UPDATED: Aug. 24- Structure of Pfizer drug is incorrect. Will re-post shortly.
2:01:27 PM: Hello, this is Leigh Krietsch Boerner live tweeting from the First-time Disclosure of Clinical Candidate session at #acs_bsoton #acsmedi

2:02:31 PM: First up is David Millan from Pfizer #acs_boston #acsmedi

2:04:11 PM: The name of the drug is PF-03715455

2:04:32 PM: The name of the drug is PF-03715455 #acs_boston #acsmedi

2:05:51 PM: It's used to treat chronic obstructive pulmonary disease (COPD), which affects 30 million people worldwide #acs_boston #acsmedi

2:07:41 PM: It's a p38 inhibitor, which is expressed and activated in the lungs of COPD patients #acs_boston #acsmedi

2:33:35 PM: Structure of Pf-03715455 #acs_boston #acsmedi

2:34:39 PM: Next up is Michael Sofia from Pharmasset, Inc. #acs_boston #acsmedi

2:35:29 PM: The name of the drugs are PSI-352938 and PSI-353661 #acs_boston #acsmedi

2:36:14 PM: It's to treat Hepatitis C, or HCV, which affects 180 million people worldwide. #acs_boston #acsmedi

2:48:51 PM: The target is NS5B-RdRP, which is part of the RNA genome of the HCV virus #acs_boston #acsmedi

3:07:11 PM: Both drugs are 2'-alpha-F, 2'-beta-C-methyl nucleoside class #acs_bsoton, #acsmedi

3:09:44 PM: PSI-352938 is in phase 1b clinical trials, PSI-353661 entering phase 1 #acs_boston #acsmedi

3:10:18 PM: Next up is Dr. Orn Almarsson #acs_boston, #acsmedi

3:11:54 PM: He is from Alkermes, which is a biotechnology company #acs_boston #acsmedi

3:13:07 PM: They are working towards treatments for reward/impulse control disorders ie substance abuse, binge eating, etc #acs_boston #acsmedi

3:14:35 PM: Target is opiod modulation #acs_boston #acsmedi

3:16:05 PM: Will discuss ALKS 33 #acs_boston #scsmedi

3:27:26 PM: Attenuates dopamine release in the NAc shell stimulated by ethanol, AMPH and cocaine #acs_boston #acsmedi

3:27:55 PM: Range from phase 1 studies to phase 2/3 #acs_boston #acsmedi

3:31:52 PM: Phase 2/3 is in alcohol dependance adaptive trial. #acs_boston #acsmedi

3:32:55 PM: Partial kappa-opiod agonist, partial delta-opiod agonist/antagonist, potent mu-opiod antagonist #acs_boston #acsmedi

3:33:53 PM: Next talk is Vincent Mascitti, discovery of nes class of SGLT2 inhibitors, from Pfizer #acs_boston #acsmedi

3:34:34 PM: Phase 2, bridged ketal series, dioxa-bicyclo[3.2.1]octane motif #acs_boston #acsmedi

3:35:19 PM: SGLT2 is sodium glucose co-transporter 2 to treat type 2 diabetes #acs_boston #acsmedi

3:37:09 PM: for review of natural product synthesis, see Washburn, W.N. J Med Chem 2009 52, 1785 #acs_boston #acsmedi

3:50:59 PM: Another paper on these molecules is V. Mascitti & C. Prville Org Lett, 2010, 12 (13), pp 2940–2943 http://bit.ly/bvdHNS #acs_boston #acsmedi

3:59:59 PM: Last talk of the session is Paul Watson from Inspire Pharmaceuticals, Inc. #acs_boston #acsmedi

4:01:01 PM: The drug is INS115644 (latrunculin B) #acs_boston #acsmedi

4:01:36 PM: It's to treat glaucoma, which is an optic neuropathy that can cause vision loss. #acs_boston #acsmedi

4:07:54 PM: Target inhibitors of actomyosin contractilily and inhibitors of microfilament assembly #acs_boston #acsmedi

4:10:30 PM: Naturally found latrunculin B is an actin plolymerication inhibitor, found in the red sea sponge #acs_boston #acsmedi

4:11:48 PM: That is actin polymerization inhibitor...#acs_boston #acsmedi

4:23:49 PM: Drug has gone through phase 1 clinical trials for proof of concept. #acs_boston #acsmedi

4:28:32 PM: That concludes the session.

Author: Carmen Drahl

Share This Post On